贝克抑郁量表-II 的症状有效性指数:在研究和临床样本中的开发和交叉验证。

IF 3 3区 心理学 Q2 CLINICAL NEUROLOGY Clinical Neuropsychologist Pub Date : 2024-11-22 DOI:10.1080/13854046.2024.2432058
Robert D Shura, Ryan W Schroeder, Anna S Ord, Rachel K Bieu, Victoria L O'Connor, Anna T Magnante, Makenna Snodgrass, Holly M Miskey, Sarah L Martindale, Jared A Rowland
{"title":"贝克抑郁量表-II 的症状有效性指数:在研究和临床样本中的开发和交叉验证。","authors":"Robert D Shura, Ryan W Schroeder, Anna S Ord, Rachel K Bieu, Victoria L O'Connor, Anna T Magnante, Makenna Snodgrass, Holly M Miskey, Sarah L Martindale, Jared A Rowland","doi":"10.1080/13854046.2024.2432058","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> The present study sought to cross validate the recently developed total score cut-off for the Beck Depression Inventory-II (BDI-II) and identify additional embedded symptom validity indices within this commonly used self-report depression measure. <b>Methods:</b> Study 1 included a research sample of 379 veterans with diagnostic subgroups of Current and Lifetime Depression and Current and Lifetime Posttraumatic Stress Disorder (PTSD). Study 2 included a clinical sample of 224 veterans with diagnostic subgroups of Current Depression, Lifetime Depression, and No Depression. Three embedded BDI-II symptom validity indices were examined in the total samples and subgroups: the BDI-II Symptom Severity Scale (total raw score), BDI-II Extreme Symptom Scale (summed frequency of extreme responses), and the BDI-II Rare Items Scale (summed frequency of rarely endorsed items). Validity indices from the Personality Assessment Inventory were utilized in both studies, with the Miller Forensic Assessment of Symptoms Test also used in Study 1. <b>Results:</b> In Study 1, BDI-II validity index cut-off scores had to be adjusted the highest for the Current Depression or Current PTSD subgroups. The cut-offs were associated with sensitivity rates ranging from 0.12 to 0.53 and specificity rates ranging from 0.90 to 0.96. In Study 2, cut-offs had to be adjusted, the highest for the Current Depression subgroup. Identified cut-offs had sensitivity rates ranging from 0.22 to 0.65 and specificity rates ranging from 0.89 to 0.95. <b>Conclusions:</b> This study supports the use of all three proposed BDI-II embedded symptom validity indices.</p>","PeriodicalId":55250,"journal":{"name":"Clinical Neuropsychologist","volume":" ","pages":"1-19"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Symptom validity indices for the Beck Depression Inventory-II: development and cross-validation in research and clinical samples.\",\"authors\":\"Robert D Shura, Ryan W Schroeder, Anna S Ord, Rachel K Bieu, Victoria L O'Connor, Anna T Magnante, Makenna Snodgrass, Holly M Miskey, Sarah L Martindale, Jared A Rowland\",\"doi\":\"10.1080/13854046.2024.2432058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> The present study sought to cross validate the recently developed total score cut-off for the Beck Depression Inventory-II (BDI-II) and identify additional embedded symptom validity indices within this commonly used self-report depression measure. <b>Methods:</b> Study 1 included a research sample of 379 veterans with diagnostic subgroups of Current and Lifetime Depression and Current and Lifetime Posttraumatic Stress Disorder (PTSD). Study 2 included a clinical sample of 224 veterans with diagnostic subgroups of Current Depression, Lifetime Depression, and No Depression. Three embedded BDI-II symptom validity indices were examined in the total samples and subgroups: the BDI-II Symptom Severity Scale (total raw score), BDI-II Extreme Symptom Scale (summed frequency of extreme responses), and the BDI-II Rare Items Scale (summed frequency of rarely endorsed items). Validity indices from the Personality Assessment Inventory were utilized in both studies, with the Miller Forensic Assessment of Symptoms Test also used in Study 1. <b>Results:</b> In Study 1, BDI-II validity index cut-off scores had to be adjusted the highest for the Current Depression or Current PTSD subgroups. The cut-offs were associated with sensitivity rates ranging from 0.12 to 0.53 and specificity rates ranging from 0.90 to 0.96. In Study 2, cut-offs had to be adjusted, the highest for the Current Depression subgroup. Identified cut-offs had sensitivity rates ranging from 0.22 to 0.65 and specificity rates ranging from 0.89 to 0.95. <b>Conclusions:</b> This study supports the use of all three proposed BDI-II embedded symptom validity indices.</p>\",\"PeriodicalId\":55250,\"journal\":{\"name\":\"Clinical Neuropsychologist\",\"volume\":\" \",\"pages\":\"1-19\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Neuropsychologist\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://doi.org/10.1080/13854046.2024.2432058\",\"RegionNum\":3,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropsychologist","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1080/13854046.2024.2432058","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究目的本研究旨在对最近开发的贝克抑郁量表-II(BDI-II)总分临界值进行交叉验证,并在这一常用的自我报告抑郁量表中找出更多的嵌入症状有效性指标。研究方法研究 1 包括 379 名退伍军人的研究样本,其诊断分组为当前和终生抑郁以及当前和终生创伤后应激障碍(PTSD)。研究 2 的临床样本包括 224 名退伍军人,其诊断分组为当前抑郁、终生抑郁和无抑郁。研究人员对全部样本和亚组样本中的三个嵌入式 BDI-II 症状有效性指数进行了检测:BDI-II 症状严重程度量表(原始总分)、BDI-II 极端症状量表(极端反应频率总和)和 BDI-II 罕见项目量表(罕见认可项目频率总和)。两项研究均使用了人格评估量表中的有效性指数,研究 1 还使用了米勒法医症状评估测试。研究结果在研究 1 中,对于当前抑郁或当前创伤后应激障碍亚组,必须对 BDI-II 效度指数临界值进行最高调整。这些临界值的灵敏度从 0.12 到 0.53 不等,特异度从 0.90 到 0.96 不等。在研究 2 中,必须对临界值进行调整,当前抑郁亚组的调整幅度最大。确定的临界值灵敏度为 0.22 至 0.65,特异度为 0.89 至 0.95。结论:本研究支持使用所有三种建议的 BDI-II 嵌入症状有效性指数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Symptom validity indices for the Beck Depression Inventory-II: development and cross-validation in research and clinical samples.

Objective: The present study sought to cross validate the recently developed total score cut-off for the Beck Depression Inventory-II (BDI-II) and identify additional embedded symptom validity indices within this commonly used self-report depression measure. Methods: Study 1 included a research sample of 379 veterans with diagnostic subgroups of Current and Lifetime Depression and Current and Lifetime Posttraumatic Stress Disorder (PTSD). Study 2 included a clinical sample of 224 veterans with diagnostic subgroups of Current Depression, Lifetime Depression, and No Depression. Three embedded BDI-II symptom validity indices were examined in the total samples and subgroups: the BDI-II Symptom Severity Scale (total raw score), BDI-II Extreme Symptom Scale (summed frequency of extreme responses), and the BDI-II Rare Items Scale (summed frequency of rarely endorsed items). Validity indices from the Personality Assessment Inventory were utilized in both studies, with the Miller Forensic Assessment of Symptoms Test also used in Study 1. Results: In Study 1, BDI-II validity index cut-off scores had to be adjusted the highest for the Current Depression or Current PTSD subgroups. The cut-offs were associated with sensitivity rates ranging from 0.12 to 0.53 and specificity rates ranging from 0.90 to 0.96. In Study 2, cut-offs had to be adjusted, the highest for the Current Depression subgroup. Identified cut-offs had sensitivity rates ranging from 0.22 to 0.65 and specificity rates ranging from 0.89 to 0.95. Conclusions: This study supports the use of all three proposed BDI-II embedded symptom validity indices.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Neuropsychologist
Clinical Neuropsychologist 医学-临床神经学
CiteScore
8.40
自引率
12.80%
发文量
61
审稿时长
6-12 weeks
期刊介绍: The Clinical Neuropsychologist (TCN) serves as the premier forum for (1) state-of-the-art clinically-relevant scientific research, (2) in-depth professional discussions of matters germane to evidence-based practice, and (3) clinical case studies in neuropsychology. Of particular interest are papers that can make definitive statements about a given topic (thereby having implications for the standards of clinical practice) and those with the potential to expand today’s clinical frontiers. Research on all age groups, and on both clinical and normal populations, is considered.
期刊最新文献
Symptom validity indices for the Beck Depression Inventory-II: development and cross-validation in research and clinical samples. Development of a Symptom Validity Index for the Beck Anxiety Inventory. Interpreting the direct- and derived-Trail Making Test scores in Argentinian children: regression-based norms, convergent validity, test-retest reliability, and practice effects. Enhanced detection of suboptimal effort in psychoeducational assessments for dyslexia. Neuropsychological normative standards for late career physicians.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1